Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

CAPS Rating: 4 out of 5

A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.

Recs

4
Player Avatar zzlangerhans (99.75) Submitted: 1/26/2011 1:40:58 PM : Underperform Start Price: $2.09 THLD Score: +12.00

Threshold has been gleefully destroying shareholder value for as long as I've been following biotech. The tried and true formula: Initiate trial. Dilute. Trial fails. Dilute. Reverse split. Initiate trial. Rinse, lather, repeat. Four years ago Threshold was impoverishing their investors with a drug called glufosfamide. Now they're doing the same thing with TH-302. Similar price, similar market cap, just another hundred million or so of investor's money blown.'

Member Avatar hiddenflem (78.08) Submitted: 2/3/2012 4:31:01 PM
Recs: 0

Might want to close this out zz.

Featured Broker Partners


Advertisement